# Lunai Bioworks Inc.: overview LNAI · Nasdaq · CIK 1527728 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/lnai.md) · [Financials](/companies/lnai/financials.md) · [Filings](/companies/lnai/filings.md) · [Insiders](/companies/lnai/insiders.md) Latest reported revenue: [$31.1k](/filings/0001731122-26-001339.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Oct 13, 2026 (XBRL us-gaap:Revenues, accession 0001731122-26-001339). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | [20.9](/filings/0001731122-26-000749.md) | [31.1 d](/filings/0001731122-26-001339.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [100.0%](/filings/0001731122-26-000749.md) | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(7054.1%)](/filings/0001731122-26-000749.md) | [(6888.6%) d](/filings/0001731122-26-001339.md) | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(12278.6%)](/filings/0001731122-26-000749.md) | [(6475.7%) d](/filings/0001731122-26-001339.md) | | Diluted EPS | $ per share | [(2.76)](/filings/0001731122-25-001544.md) | [(0.45)](/filings/0001731122-26-000253.md) | [0.00](/filings/0001731122-26-000749.md) | not reported | [0.13](/filings/0001731122-25-001544.md) | [(0.08)](/filings/0001731122-26-000253.md) | [(0.10)](/filings/0001731122-26-000749.md) | not reported | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | [(1,027) d](/filings/0001731122-26-000749.md) | [(1,841) d](/filings/0001731122-26-001339.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | [0.1](/filings/0001731122-26-001339.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | [(16729.4%)](/filings/0001731122-26-001339.md) | | Net margin | % | not reported | not reported | not reported | not reported | [(6852.0%)](/filings/0001731122-26-001339.md) | | Diluted EPS | $ per share | [(2.16)](/filings/0001731122-23-001770.md) | [(0.71)](/filings/0001731122-25-000252.md) | [(0.91)](/filings/0001731122-25-001316.md) | [(86.27)](/filings/0001731122-26-001339.md) | [(1.06)](/filings/0001731122-26-001339.md) | | Free cash flow | $m | [(15.7)](/filings/0001731122-23-001770.md) | [(11.8)](/filings/0001731122-25-000252.md) | [(11.0)](/filings/0001731122-25-001316.md) | not reported | [(5.3)](/filings/0001731122-26-001339.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lnai/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Ground Swell Capital, LLC](/funds/1534450.md) | 2026-06-30 | $174.0k | 53,211 | | New +53,211 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $79.0k | 24,156 | | New +24,156 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $77.4k | 23,683 | | New +23,683 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $52.6k | 16,081 | | New +16,081 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $52.0k | 15,906 | | New +15,906 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $28.3k | 8,642 | | New +8,642 | | [ROYAL BANK OF CANADA](/funds/1000275.md) | 2026-06-30 | $5.0k | 1,687 | | New +1,687 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $4.6k | 1,405 | | New +1,405 | | [GROUP ONE TRADING LLC](/funds/932540.md) | 2026-06-30 | $1.8k | 544 | | New +544 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.1k | 326 | | New +326 | ## Recent filings [All 598 filings](/companies/lnai/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 21:38 ET | [8-K](/filings/0001731122-26-001362.md) | 3.01 Delisting notice; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-001362 | | 2026-10-15 | 21:13 ET | [SCHEDULE 13D/A](/filings/0001214659-26-012970.md) | Ownership report, active investor, amended | 0001214659-26-012970 | | 2026-10-13 | 16:55 ET | [10-K](/filings/0001731122-26-001339.md) | Annual report, period 2026-06-30 | 0001731122-26-001339 | | 2026-10-09 | 14:00 ET | [8-K](/filings/0001731122-26-001333.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-001333 | | 2026-06-17 | 16:32 ET | [8-K](/filings/0001731122-26-000871.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-000871 | | 2026-06-16 | 16:00 ET | [8-K](/filings/0001731122-26-000865.md) | 8.01 Other events | 0001731122-26-000865 | | 2026-05-20 | 09:15 ET | [8-K](/filings/0001731122-26-000759.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-000759 | | 2026-05-15 | 16:46 ET | [10-Q](/filings/0001731122-26-000749.md) | Quarterly report, period 2026-03-31 | 0001731122-26-000749 | | 2026-05-13 | 16:45 ET | [8-K](/filings/0001731122-26-000718.md) | 5.07 Shareholder vote results | 0001731122-26-000718 | | 2026-05-11 | 17:30 ET | [8-K/A](/filings/0001731122-26-000705.md) | 3.01 Delisting notice | 0001731122-26-000705 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001731122-26-001339.md), filed Oct 13, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1527728 - Tickers: LNAI - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 06:04 ET. No prices; not investment advice.